This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 27/11/2456    most recent ATVBAHA.107.152835v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mita, T. Articles by Kawamori, R. Search for Related Content PubMed PubMed Citation Articles by Mita, T. Articles by Kawamori, R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB (L)-PHENYLALANINE CYCLOHEXANE Medline Plus Health Information Diabetes

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27:2456.)
© 2007 American Heart Association, Inc.

Atherosclerosis and Lipoproteins

Nateglinide Reduces Carotid Intima-Media Thickening in Type 2 Diabetic Patients Under Good Glycemic Control

Tomoya Mita; Hirotaka Watada; Tomoaki Shimizu; Yoshifumi Tamura; Fumihiko Sato; Takahiro Watanabe; Jong Bock Choi; Takahisa Hirose; Yasushi Tanaka; Ryuzo Kawamori

From the Department of Medicine, Metabolism, and Endocrinology, Juntendo University School of Medicine, Tokyo, Japan.

Correspondence to A/Prof. Hirotaka Watada, MD, PhD, Department of Medicine, Metabolism, and Endocrinology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. E-mail hwatada{at}med.juntendo.ac.jp

Objective— Postprandial hyperglycemia observed in type 2 diabetes mellitus is a risk factor for atherosclerosis. The aim of this study was to investigate the effect of strict glycemic control by nateglinide on common carotid far wall intima-media thickness in type 2 diabetic patients who were already under good glycemic control.

Methods and Results— We performed an open labeled randomized prospective trial on 78 drug-naive type 2 diabetic patients whose HbA₁c was less than 6.5%. Thirty-eight patients were randomly assigned to receive nateglinide (270 mg/dL) and 40 to control group (no treatment). After 12 months, a significant reduction in HbA₁c was observed in the nateglinide group, whereas a significant increase of HbA₁c was observed in the untreated group. The carotid intima-media thickness at the end of 1-year follow-up was significantly reduced in the nateglinide group compared with the untreated group (–0.017±0.054 mm/year versus 0.024±0.066 mm/year, P=0.0064). Whereas nateglinide treatment also reduced triglyceride, highly-sensitive C-reactive protein, and E-selectin, multiple regression analysis identified HbA₁c as the only significant independent determinant of the change in carotid intima-media thickness.

Conclusion— In type 2 diabetic patients with good glycemic control, further strict glycemic control by nateglinide results in regression of carotid intima-media thickness.

To investigate the effect of nateglinide on atherosclerosis, we performed an open labeled randomized prospective trial on drug-naive type 2 diabetic patients whose HbA₁c was less than 6.5%. The carotid intima-media thickness at the end of 1-year follow-up period was significantly decreased in the nateglinide group compared with the untreated group. In type 2 diabetic patients under good glycemic control, further strict glycemic control by nateglinide results in regression of carotid intima-media thickness.

Key Words: intima-media thickness • atherosclerosis • strict glycemic control • postprandial hyperglycemia • type 2 diabetes

This article has been cited by other articles:

				I. Raz, P. W.F. Wilson, K. Strojek, I. Kowalska, V. Bozikov, A. K. Gitt, G. Jermendy, B. N. Campaigne, L. Kerr, Z. Milicevic, et al. Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial Diabetes Care, March 1, 2009; 32(3): 381 - 386. [Abstract] [Full Text] [PDF]